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a b s t r a c t
A facile synthesis of the side chain of loteprednol etabonate, namely, chloromethyl-17-[(ethoxy-
carbonyl))oxy]-11-hydro of loteprednol etabonate, viz., chloromethyl-17-[(ethoxycarbonyl))oxy]-
11xy-3-oxoandrosta-1,4-diene-17-carboxylate – an ocular soft corticosteroid, has been described start-
ing from a 20-oxopregnane, namely, 3-acetoxy-pregn-5(6),16(17)-diene-20-one (16-dehydropregne-
nolone acetate, i.e., 16-DPA) using our recently developedmetal-mediatedhalogenation as a key reaction.vailable online 26 January 2011
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etal mediated halogenation
nti-inﬂammatory agents
Corticosteroidshavedemonstratedexcellent anti-inﬂammatory
ctivity in clinical practice. However, their therapeutic effects are
ften accompanied by toxicity [1]. Hence, the search for improved
opical corticosteroids with less toxicity has been a major goal in
harmaceutical research and development in recent years. Bodor
nd his coworkers [2–4] introduced the concept of ‘soft drug’ by
eans of designing pharmaceutical agents of reduced toxicity
ith structural modiﬁcation to achieve a satisfactory therapeutic
ndex [5–10]. ‘Loteprednol etabonate’, namely, chloromethyl
7-[(ethoxycarbonyl))oxy]-11-hydroxy-3-oxoandrosta-1,4-
iene-17-carboxylate 1, which has recently been marketed as an
cular anti-inﬂammatory agent, is a soft corticosteroid developed
n the concept of Bodor and his group [5–7]. The synthesis of a soft
rug is achieved by starting with a known inactive metabolite of a
nown drug. The inactive metabolite is then modiﬁed to an active
orm that after having achieved its therapeutic role, undergoes
predictable and controllable one- or two-step transformation
n vivo back to the inactive metabolite via known process of
nzymatic deactivation [11,12]. Loteprednol etabonate 1 is one
f the ﬁrst-generation cortienic acid-based soft corticosteroids to
et approved by Food and Drug Administration (FDA) for use in all
nﬂammatory and allergy-related ophthalmic disorders [4].
∗ Corresponding author. Tel.: +91 376 2370 121x2362; fax: +91 376 2370 011.
E-mail address: pritishchowdhury@yahoo.com (P. Chowdhury).
1 Present address: IIT Guwahati Campus, North Guwahati, India.
039-128X/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
oi:10.1016/j.steroids.2011.01.006In loteprednol etabonate, a metabolically labile ester function
occupies a 17-position, while a stable carbonate group occu-
pies the 17-position. The ester is hydrolysed to an inactive
carboxylic acid, 1-cortienic acid etabonate, and then into 1-
cortienic acid in biological systems [9–14]. As a result of the
predictable conversion of loteprednol etabonate into an inactive
metabolite in the eye following topical administration, this cor-
ticosteroid has a low propensity for undesirable toxicity while
possessing increased anti-inﬂammatory activity. In fact, this drug
has been found to be 1.5 times more potent than the parent anti-
inﬂammatory agent dexamethasone. Clinical trials on these drugs
are also going on for a safer treatment of gastrointestinal inﬂam-
mation [13].
In continuation of ourwork on steroid transformations [15–21],
we recently introduced a potential method of metal-mediated
halogenation of 20-oxopregnane, namely, 16-DPA and its rela-
tives using the system MnO2–TMSCl/AcCl–AcOH giving an almost
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Scheme 1. Reagents and conditions: (i) H2, Pd–C, 95%, (ii) MnO2–TMSCl/AcCl–AcOH, 81%, (iii) 3% KOH, MeOH–H2O, 75%, (iv) LiAlH4, THF, 88%, (v) CAN, AcOH, 75%, (vi)
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y-CPBA, CHCl3, 62%, (vii) H2SO4, acetone–H2O, 48%, (viii) Jones reagent, 57%, (ix) Os
uantitative yield of 17, 21-dichloro 20-oxo-pregnanes. In the
resent work, using this halogenation as a key reaction, a short
nd convenient method for the construction of the side chain of
oteprednol etabonate1has beendeveloped from20-oxopregnane,
amely, 3-acetoxy-pregn-5(6),16(17)-diene-20-one (16-DPA) 2,
hich is readily available in the laboratory and therefore,
ad been taken as the model starting material (Scheme 1)
18].
16-DPA 2 was hydrogenated by Pd/C to form 3-acetoxy-
-pregnan-20-one 3 in quantitative yield and was subjected to
hlorination using our reagent system MnO2–TMSCl/AcCl–AcOH
o give 17, 21-dichloro-3-acetoxy-5-pregnan-20-one 4 in very
igh yield.
Favorskii rearrangement of the compound 4, under mild basicondition with 3% KOH in methanol–water (85:15) followed
y concomitant deacetylation of 3-acetoxy group furnished
17(20)-20-methoxycarbonyl derivative, namely, pregn-17(20)-
ne-3-ol-21-oic acid methyl ester 5 also in almost quantitative
ield [15,16].2O2, rt., 50%, (x) NaIO4, Ethyl chloroformate, 70% and (xi) chloromethyl iodide, 75%.
Favorskii rearrangementproduct5was then subjected tometal-
mediated reduction by using lithium aluminium hydride (LiAlH4)
at room temperature in ether or THF which furnished the alco-
hol derivative, pregn-17(20)-ene-3, 21-diol 6 in high yield. The
compound 6 was acetylated by the newly reported method [19]
in acetic acid in the presence of ceric ammonium nitrate (CAN) to
obtain the acetylated product, 3, 21-diacetoxy-pregn-17(20)-ene
7 in quantitative yield.
Compound 7 was then epoxidised with m-chloroperbenzoic
acid (m-CPBA) which, after puriﬁcation by preparative thin
layer chromatography (TLC) furnished two isomeric epoxides,
3, 21-diacetoxy-17,20-epoxy-5-pregnane 8a and 3,21-
diacetoxy-17,20-epoxy-5-pregnane 8b. The mass spectrum of
both the products showed a molecular ion peak at 418 (M+) and
in 1H NMR spectrum, both showed a multiplet at near 3.0ppm for
C-20 proton under the epoxide ring.
The major epoxide 8a was assigned to have a 17-
orientation because of its favourable formation due to the
steric factor [22–24] associated with the steroid molecule and
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ence the minor epoxide 8b was assigned to have a 17-
rientation.
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Acid-induced epoxide ring opening reaction was carried out on
he major epoxide 8a to get the desired compound 9 with a 17-
ydroxy group. Although perchloric acid iswidely used for opening
p of an epoxide ring, the use of this acid led to almost complete
ydrolysis of C-3 and C-21 acetate groups of the compound 8a
iving poor yield of the desired diol 3, 21-diacetoxy-5-pregnan-
7, 20-diol 9, even when the acid was used in low concentration.
The use of sulphuric acid in aqueous acetone was used as a
eagent of choice because of the fact that it does not affect hydrol-
sis of the acetate groups present in a steroid molecule [25] which
s desirable in this case for the future operation and also would fur-
ish the diol 9 having the requisite 17-orientation of the hydroxyl
roup from the -epoxide 8a, irrespective of cis or trans opening
ue to preferential nucleophilic attack on its C-20 carbon atom as
epicted in Scheme 1. Thus, when this epoxide was treated with a
mall amount of concentrated sulphuric acid in aqueous acetone,
t yielded the desired compound, 3,21-diacetoxy-5-pregnan-
7,20-diol 9 in good yield. Themass spectrumof the product after
uriﬁcation exhibited molecular ion peak at 436(M+). IR spectrum
onﬁrmed the presence of both hydroxyl (3400 cm−1) and acetate
roups (1730 cm−1) in compound 9.
Compound 9 was then oxidised by Jones reagent at low
emperature to furnish 20-oxo compound 3,21-diacetoxy-5-
regnan-17-ol-20-one 10, which is the immediate precursor
or constructing the side chain of loteprednol etabonate 1. The
ass spectrum of the compound exhibited molecular ion peak at
34(M+). The IR spectrum displayed a band at 1710 cm−1 besides
isplaying acetate bands at 1730 cm−1.
17-Hydroxy hydrocortisone derivative 10 was also directly
btained from the oleﬁn 7 by the oxidative hydroxylation reac-
ion with hydrogen peroxide in the presence of a small amount of
smium tetroxide. Several workers have reported [26–31] the syn-
hesis of 17,20-dihydroxy steroid derivatives and 17-hydroxy
ydrocortisone using osmium tetroxide alone or in combination
ith various oxidants such as phenyl iodoacetate, H2O2, NMO,
3[Fe(CN)6]. It has been established that 17-hydroxyl conﬁgu-
ation is a consequence of the rearward attack upon the 17–20
ouble bond (-face) of the steroid molecule and further by the
irtue of the cis addition of osmium tetroxide. A similar behaviour
f osmium tetroxidewas reported byWoodward and Brutcher [27]
n the hydroxylation of steroid oleﬁns wherein it led to the forma-
ion of cis-diol by direct attack from the most accessible -face of
he rigid steroidmolecule. Recently Jonsson et al. [32] reported cis-
ydroxylation of trans-5-decene using OsO4–NMM with the aid of
triple catalytic system using H2O2 as the terminal oxidant to sup-
ress over-oxidation, namely, oxidative hydroxylation as has been
ound to occur in the case of steroidal oleﬁns as mentioned above.
he product obtained from 9 by its oxidation and that obtained
y oxidative hydroxylation of 7 were found to be identical in all
espects (superimposable IR, NMR, and Mass spectra) including
heir TLC behaviour showing that both the products were the same
ompound 10.
To conﬁrm its structure further, compound 10 was hydrolysed
ith 3% KOH in MeOH–H2O which furnished a polar compounds 76 (2011) 497–501 499
5-pregnan-3, 17, 21-triol-20-one 12. The compound exhibited
the molecular ion peak at 350(M+). The IR spectrum exhibited a
broad band at 3300–3400 cm−1 for the three hydroxyl groups and
another at 1710 cm−1 for the C-20 carbonyl group present in the
molecule.
HO
H
OH
O
OH
   12 
Conversion of compound 10 to get the requisite side chain of
loteprednol etabonate 1 is well known [6], which involves the peri-
odic acid oxidation cumdegradationwith sodiummetaperiodate to
cortienic acid derivative followed by carboxylation of 17-hydroxy
group with ethyl chloroformate and the esteriﬁcation of 17-
carboxylic acid with chloromethyl iodide. These steps provide the
desired 17-ester functionality and 17-carbonate functionality
present in loteprednol etabonate and related drugs.
Thus the present methodology paves a useful way to con-
struct the side chain of loteprednol etabonate – an ocular
soft corticosteroid directly from 20-oxopregnanes via its C-
21 functionalisation in a much simpler and easier way with
this newly developed metal-mediated halogenation technique
which avoids harsh and tedious reaction conditions [33–36]
associated with this conversion. It is pertinent to note that
C-21 functionalised 20-oxopregnanes are important and useful
intermediates for synthesising corticosteroids and many other
recently developed steroidal drugs including anti-inﬂammatory
agents, hormones, oral contraceptives, and anabolic steroids
[33,37–40]
1. Experimental
1.1. General methods
Meltingpointsweredeterminedwithanelectrothermalmelting
point apparatus and are uncorrected. All the chemicals used were
of reagent grade of E. Merck and were used without further puriﬁ-
cation. The progress of each of the reactions was monitored on TLC
using silica gel (E. Merck) and the plates were activated at 120 ◦C
before use. IR spectra were recorded with a Perkin–Elmer model
2000 series FT-IR spectrometer (Perkin Elmer Limited, Beacons
Field Budes, UK) for solutions in chloroform. Infrared absorbance
is reported in reciprocal centimetre (cm−1). 1H and 13C NMR
spectra were recorded on a Bruker DPX (300MHz) spectrometer
(Fallanden, Switzerland) using CDCl3 or DMSO-d6 as solvent with
tetramethylsilane (TMS) as internal standardonppmscale (ı).Mul-
tiplicity of the resonance peaks is indicated as singlet (s), broad
singlet (bs), doublet (d), triplet (t), quartet (q), and multiplet (m).
Mass spectrometric analysis was performed by positivemode elec-
trospray ionisation with a Bruker Esquire3000 LC-MS instrument
(Bruker Daltonics, Germany). Elemental analysis was carried out
in Varian CHN Analyzer (Perkin - Elmer US Instrument Division,
Norwalk, USA).
1.2. 3ˇ-Acetoxy-5˛-pregnan-20-one 3Two grams of 16-DPA 2 in 100ml of ethanol was hydrogenated
at 45psi using 500mg of 5% Pd/C for a period of 10h. The reaction
mixture was ﬁltered and alcohol was distilled off under reduced
pressure to furnish the crude hydrogenated product which was
puriﬁedby columnchromatographyover silica gel using petroleum
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ther and ethyl acetate as the eluent to furnish 3-acetoxy-5-
regnan-20-one 3 in pure form.
Yield: 1.9 g (95%); Mp: 172 ◦C; IR (cm−1): 1735, 1700, 1450,
200; 1H NMR (CDCl3): 0.9 (s, 3H, Me), ı 1.0 (s, 3H, Me), 0.9–1.9
m, 23H, –CH and –CH2), 2.0 (s, 3H, OAc), 2.2 (s, 3H, COMe), 4.3
m, 1H, H-3); 13C NMR: ı 34.2(C-1), 35.1(C-2), 78.6(C-3), 39.5(C-4),
1.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9), 35.4(C-
0), 20.9(C-11), 39.5(C-12), 40.5(C-13), 55.4(C-14), 34.7(C-15),
2.9(C-16), 69.5(C-17), 16.7(C-18), 15.2(C-19), 172.9(C–OCOCH3),
12.5(C-20), 21.3(C-21); mass spectrum (mz−1): 360 (M+), 318,
00, 298, 257; Anal. Calcd. for C23 H36 O3: C,76.66; H, 8.91; found:
,76.41; H,9.03.
.2.1. 17˛,21-Dichloro-3ˇ-acetoxy-5˛-pregnan-20-one 4
To a solution of 200mg of 3-acetoxy-5-pregnan-20-one 3 in
0ml of glacial acetic acid was added excess of MnO2 (170mg) and
hen 1ml of AcCl or 4ml of TMSCl. The reaction mixture was kept
vernight at room temperature. Then, the reaction mixture was
oured into cold water and extracted with petroleum ether. The
rganic extract after drying over anhydrous sodium sulphate was
vaporated under reduced pressure to furnish a residue which was
uriﬁed by preparative TLC (EtOAc:petroleum ether: 1:12,v/v) to
et 17,21-dichloro-3-acetoxy-5-pregnan-20-one 4 as solid.
Yield: 190mg (81%); MP: 160 ◦C; IR (cm−1): 1730, 1710, 1445,
200; 1H NMR (CDCl3): 0.9 (s, 3H, Me), ı 1.0 (s, 3H, Me), 0.9–2.0 (m,
2H, –CH and –CH2), 2.1 (s, 3H, OAc), 4.2 (d, J=1.5Hz, 2H, H-21),
.5 (m, 1H, H-3); 13CNMR: ı 34.2(C-1), 35.1(C-2), 78.6(C-3), 39.5(C-
), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9), 35.4(C-10),
0.9(C-11), 39.5(C-12), 40.5(C-13), 55.4(C-14), 34.7(C-15), 22.9(C-
6), 89.7 (C-17), 16.7(C-18), 15.2(C-19), 171.2(C-OCOCH3), 192.6
C-20), 50.2(C-21); mass spectrum (mz−1): 428 (M+), 430 (M++2),
32 (M++4), 392, 368, 332; Anal. Calcd. for C23 H34 O3Cl2: C,64.49;
,7.94; found: C,64.46; H,7.89.
.2.2. Pregn-17(20)-ene-3ˇ-ol-21-oic acid methyl ester 5
Two-hundred milligrams of the compound 17,21-dichloro-
-acetoxy-5-pregnan-20-one 4was allowed to stir with 3% KOH
n MeOH–H2O (85:15) at room temperature for a period of 3h.
he reaction was monitored on TLC. When TLC indicated that the
tarting material had all been used up, the reaction mixture was
oured into cold water and was acidiﬁed with citric acid. It was
hen extracted with CH2Cl2 (3×150ml). The organic extract was
ried over anhydrous Na2SO4 and was evaporated under reduced
ressure. The residue so obtained was puriﬁed by preparative TLC
EtOAc:petroleum ether: 1:5, v/v) to get the pure pregn-17(20)-
ne-3-ol-21-oic acid methyl ester 5 in the form of a gum.
Yield: 120mg (75%); IR (cm−1): 3400, 1730, 1250; 1H NMR
CDCl3): ı 0.8 (s, 3H, Me), 1.0 (s, 3H, Me), 0.9–2.1 (m, 23H, –CH and
CH2), 2.4 (m, 1H, 3-OH), 3.4 (s, 3H, OMe), 3.6 (m, 1H, H-3), 5.3
s, 1H, H-20); 13C NMR: ı 34.2(C-1), 35.1(C-2), 67.6 (C-3), 39.5(C-
), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9), 35.4(C-10),
0.9(C-11), 39.5(C-12), 40.5(C-13), 55.4 (C-14), 32.7(C-15), 36.6(C-
6), 164.8 (C-17), 16.7(C-18), 15.2(C-19), 114.8C-20), 167.9(C-21),
2.7(C–OCH3); Mass spectrum (mz−1): 346 (M+), 328, 288, 270;
nal. Calcd. for C22H34 O3: C,76.30; H,9.83; found: C,76.21; H,9.76.
.2.3. Pregn-17(20)-ene-3ˇ,21-diol 6
Five-hundredmilligramsof substrate5wasdissolved in25mlof
nhydrous THF. The reaction was allowed to stir at room tempera-
ure and to itwas added300mgLiAlH4. Themixturewas allowed to
tir for 4h andwasmonitored on TLC.When TLC indicated comple-
ionof the reaction, the reactionmixturewasﬁlteredand theﬁltrate
as poured into cold water and was extracted with CH2Cl2. The
rganic extract after drying over anhydrous Na2SO4 was distilled
nder reduced pressure to get a residue. The residue was puriﬁed
y preparative TLC, which furnished a solid product pregn-17(20)-
ne-3,21-diol 6.s 76 (2011) 497–501
Yield: 400mg (88%); M.P: 181 ◦C; IR (cm−1): 3300, 1350, 1250;
1H NMR (DMSO-d6): 0.9 (s, 3H, Me), ı 1.0 (s, 3H, Me), 0.9–2.1 (m,
22H, –CH and –CH2), 3.5 (m, 3H, H-3 and H-21), 3.8–4.1 (m, 2H,
3- and 21-OH), 5.3 (m, 1H, H-21); 13C NMR: ı 34.2(C-1), 35.1(C-
2), 67.6 (C-3), 39.5(C-4), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8),
46.2(C-9),35.4(C-10), 20.9(C-11), 39.5(C-12), 40.5(C-13), 55.4(C-
14), 32.7(C-15), 36.6(C-16), 152.3(C-17), 16.7(C-18), 15.2(C-19),
114.9(C-20), 64.6(C-21); mass spectrum (mz−1): 318 (M+), 300,
283, 253; Anal. Calcd. for C21 H34 O2: C,79.25; H,10.69; found:
C,79.18; H,10.03.
1.2.4. 3ˇ, 21-Diacetoxy-pregn-17(20)-ene 7
To a solution of 500mg of pregn-17(20)-ene-3, 21-diol 6 in
20ml of glacial AcOH was added 50mg of CAN. The reaction mix-
ture was heated in the range 50–60 ◦C and was monitored on
TLC. After completion of the reaction, the reaction mixture was
poured into cold water and was extracted with petroleum ether.
The organic extract was dried over anhydrous Na2SO4 and was
distilled under reduced pressure to get a residue which was puri-
ﬁed by preparative TLC (EtOAc:petroleum ether: 1:10) to furnish
3,21-diacetoxy-pregn-17(20)-ene 7 in pure form as a solid.
Mp: 154 ◦C; yield: 450mg (75%); IR (cm−1): 1725 (broad), 1350,
1250; 1H NMR (CDCl3): ı 0.9 (s, 3H, Me), 1.1 (s, 3H, Me), 0.8–1.9
(m, 22H, –CH and –CH2), 2.0 (bs, 6H, OAc), 4.3–4.5 (m, 3H, H-3 and
H-21), 5.3 (m, 1H, H-20); 13C NMR: ı 34.2(C-1), 35.1(C-2), 72.4 (C-
3), 39.5(C-4), 41.9(C-5), 28.1(C-6),32.0(C-7), 29.0(C-8), 46.2(C-9),
35.4(C-10), 20.9(C-11), 39.5(C-12), 40.5(C-13), 53.6(C-14), 32.7(C-
15), 36.6(C-16), 152.3(C-17), 16.7(C-18), 15.2(C-19), 114.9(C-20),
71.7(C-21), 173.1(C-OCOCH3); mass spectrum (mz−1): 402 (M+),
360, 342, 284; Anal. Calcd. for C25 H38 O4: C,74.63; H,9.45; found:
C,74.51; H,9.39.
1.2.5. 3ˇ, 21-Diacetoxy-17˛, 20˛-epoxy-5˛-pregnane 8a and
3ˇ, 21-diacetoxy-17ˇ, 20ˇ-epoxy-5˛-pregnane 8b
To a solution of 500mg of 3,21-diacetoxy-pregn-17(20)-ene 7
in 20ml of chloroform added 150mg ofm-CPBA. The reactionmix-
ture was kept overnight at room temperature. On the following
day, TLC indicated the formation of two polar products. The reac-
tion mixture was then poured into cold water and was extracted
with dichloromethane. The organic extract was washed ﬁrst with
an aqueous solution of sodiummeta-bisulphite and then with a 5%
NaOHaqueous solution. Finally theorganic extract afterdryingover
anhydrous Na2SO4 was distilled under reduced pressure to furnish
a residuewhichwas puriﬁed by preparative TLC (EtOAc:petroleum
ether: 1:1) to give 8a as the major and 8b as the minor products.
Yield: 8a: 320mg (62%); IR (cm−1): 1730 (broad), 1350, 1260;
1H NMR (CDCl3): ı 0.9 (s, 3H, Me), 1.0 (s, 3H, Me), 0.91-1.9 (m, 22H,
–CH and –CH2), 2.1 (bs, 6H, OAc), 3.1 (m, 1H, H-20), 4.3–4.5 (m, 3H,
H-3 and H-21)); 13C NMR (CDCl3): ı 34.2(C-1), 35.1(C-2), 72.4 (C-
3), 39.5(C-4), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9),
35.4(C-10), 20.9(C-11), 39.5(C-12), 40.5(C-13), 53.6(C-14), 32.7(C-
15), 36.6(C-16), 74.3(C-17), 16.7(C-18), 15.2(C-19), 57.2(C-20),
72.4(C-21), 173.1(C–OCOCH3); mass spectrum (mz−1): 418 (M+),
376, 258, 200,184; Anal. Calcd. for C25 H38 O5: C,71.77; H,9.09;
found: C,71.72; H,9.00.
Yield: 8b: 100mg (20%); IR (cm−1): 1735 (broad), 1340, 1250;
1H NMR (CDCl3): ı 0.9 (s, 3H, Me), 1.0 (s, 3H, Me), 0.9–1.9 (m, 22H,
–CH and –CH2), 2.0 (bs,6H, OAc), 3.3 (m, 1H, H-20), 4.4–4.6 (m, 3H,
H-3 and H-21); 13C NMR (CDCl3): ı34.2(C-1), 35.1(C-2), 72.4 (C-
3), 39.5(C-4), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9),
35.4(C-10), 20.9(C-11), 39.5(C-12), 40.5(C-13), 53.6(C-14), 32.7(C-
15), 36.6(C-16), 74.3(C-17),16.7(C-18), 15.2(C-19), 57.2(C-20), 72.4
(C-21), 173.1(C–OCOCH3); mass spectrum (mz−1): 418 (M+), 376,
258, 200,184; Anal. Calcd. for C25 H38 O5: C,71.77; H,9.09; found:
C,71.67; H,8.94.
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.2.6. 3ˇ, 21-Diacetoxy-5˛-pregnan-17˛, 20-diol 9
To a solution of 200mg of 3, 21-diacetoxy-17, 20-epoxy-
-pregnane 8a in 10ml of acetone were added 2ml of water and
drops of concentrated H2SO4. The resulting solution was allowed
o stand at room temperature for 24h. The reaction mixture was
oured into cold water and was extracted with dichloromethane.
he extract after drying over anhydrous sodium sulphate was dis-
illed under reduced pressure to get a residue which was puriﬁed
y preparative TLC (EtOAc:petroleum ether: 1:1) to furnish 3, 21-
iacetoxy-5-pregnan-17, 20-diol 9.
Yield: 110mg (48%); IR (cm−1): 3400, 1735 (broad), 1345, 1250;
H NMR (DMSO-d6): ı 0.9 (s, 3H, Me), 1.1 (s, 3H, Me), 0.9–1.9 (m,
4H, –CH and –CH2), 2.1 (bs, 6H, OAc), 3.4 (m, 1H, H-20), 3.9 (m,
H, 17- and 20-OH), 4.4–4.6 (m, 3H, H-3 and H-21); 13C NMR:
34.2(C-1), 35.1(C-2), 72.4 (C-3), 39.5(C-4), 41.9(C-5), 28.1(C-6),
2.0(C-7), 29.0(C-8), 46.2(C-9), 35.4(C-10), 20.9(C-11), 39.5(C-12),
0.5(C-13), 53.6(C-14), 32.7(C-15), 36.6(C-16), 85.2(C-17), 16.7(C-
8), 15.2(C-19), 79.1(C-20), 69.2(C-21), 173.1(C-OCOCH3); Mass
pectrum (mz−1): 436 (M+), 418, 376, 300; Anal. Calcd. for C25 H40
6: C,68.81; H,9.17; found: C,68.76; H,9.09.
.2.7. 3ˇ, 21-Diacetoxy-5˛-pregnan-17˛-ol-20-one 10
.2.7.1. Reaction A: from oxidation of compound 9. A solution of
00mg of 3, 21-diacetoxy-5-pregnan-17, 20-diol 9 in 20ml
f dry acetone (distilled over KMnO4) was cooled to 0–10 ◦C in an
ce bath and to it was added 5 drops of Jones reagent and kept
nder stirring for a period of 1h. The reaction was monitored on
LC. When TLC indicated the completion of the reaction, 3ml of
ethanolwas added and poured into coldwater. The reactionmix-
ure was extracted with CH2Cl2. The organic extract after drying
ver anhydrousNa2SO4 was distilled under reducedpressure to get
residuewhichwas puriﬁed by preparative TLC (EtOAc:petroleum
ther: 1:5) to furnish the compound3, 21-diacetoxy-5-pregnan-
7-ol-20-one 10 in pure form.
Yield: 115mg (57%); IR (cm−1): 3400, 1730 (broad), 1710, 1250;
H NMR (CDCl3); ı 0.8 (s, 3H, Me), 1.1 (s, 3H, Me), 0.9–1.9 (m, 23H,
CH and –CH2), 2.0 (bs, 6H, OAc), 2.4 (bs, 17-OH), 4.3–4.5 (m, 3H,
-3 and H-21); 13C NMR (CDCl3): ı 34.2(C-1), 35.1(C-2), 73.8(C-
), 39.5(C-4), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9),
5.4(C-10), 20.9(C-11), 39.5(C-12), 40.5(C-13), 53.6(C-14), 32.7(C-
5), 36.6(C-16), 97.7(C-17), 16.7(C-18), 15.2(C-19), 212.1(C-20),
2.4(C-21), 173.1(C–OCOCH3); Mass spectrum (mz−1): 434 (M+),
16, 374, 356, 298; Anal. Calcd. for C25 H38 O6:C,69.12; H,8.76;
ound: C,69.02; H,8.68.
.2.8. Reaction B: from oxidative hydroxylation of compound 7
To a solution of 402mg (1mmol) of the oleﬁn 7 in acetone (5ml)
nd H2O (15ml) at room temperature was added OsO4 (375l,
.5wt%, 0.03mmol) followed by H2O2 (310l, 30% aq., 3mmol).
he reaction mixture was stirred for a period of 20h at room tem-
erature and then quenched by the addition of Na2S2O4 (150mg)
ndmagnesium silicate (300mg). The reactionmixturewas further
tirred for another 3h and diluted with ethyl acetate (50ml) and
hen ﬁltered through a pad of celite and the celite bed was thor-
ughly washedwith ethyl acetate. After that, solvent was removed
nder reduced pressure to get a residue which was puriﬁed by
reparative TLC using ethyl acetate and hexane as the eluents.
Yield: 220mg (50%); IR, NMR,mass, and TLC are superimposable
ith those of the compound 3,21-diacetoxy-5-pregnan-17-
l-20-one 10. Anal. Calcd. for C25 H38 O6: C,69.12; H,8.76; found:
,69.01; H,8.69.
.2.9. 5˛-Pregnan-3ˇ, 17˛, 21-triol-20-one 12
200mg of 3, 21-diacetoxy-5-pregnan-17-ol-20-one 10was
ydrolysed with 50ml of 3% KOH in MeOH–water. The reaction
[
[
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mixture was allowed to stir for a period of 2 h and was monitored
on TLC. After completion of the reaction, the reaction mixture was
poured into cold water and was acidiﬁed with an aqueous solution
of citric acid. It was then extractedwith CH2Cl2. The organic extract
after drying over anhydrous Na2SO4 was distilled under reduced
pressure to get a residue which was puriﬁed by preparative TLC to
furnish 5-pregnan-3,17,21-triol-20-one 12
Yield:125mg(78%); IR (cm−1): 3300–3400,1710,1250; 1HNMR
(DMSO-d6): ı 0.9 (s, 3H, Me), 1.0 (s, 3H, Me), 0.9–1.8 (m, 22H, –CH
and –CH2), 3.4 (m, 3H, H-3 and H-21), 4.2–4.4 (m, 3H, 3, 17-
and 21-OH); 13C NMR: ı 34.2(C-1), 35.1(C-2), 70.6(C-3), 39.2(C-
4), 41.9(C-5), 28.1(C-6), 32.0(C-7), 29.0(C-8), 46.2(C-9), 35.4(C-10),
20.9(C-11), 39.5(C-12), 40.5(C-13), 53.6(C-14), 27.2(C-15), 68.1(C-
16), 101.8(C-17), 16.7(C-18), 15.2(C-19), 213.6(C-20), 70.6(C-21);
mass spectrum (mz−1): 350 (M+), 332, 314, 296; Anal. Calcd. for
C21 H34 O4: C,72.00; H,9.71; found: C,71.89; H,9.61.
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